Cholesterol emboli syndrome medical therapy
|
Cholesterol emboli syndrome Microchapters |
|
Differentiating Cholesterol emboli syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Cholesterol emboli syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Cholesterol emboli syndrome medical therapy |
|
Directions to Hospitals Treating Cholesterol emboli syndrome |
|
Risk calculators and risk factors for Cholesterol emboli syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]
Overview
Some pharmacologic medical therapies that can be effective for cholesterol emboli syndrome include statins, corticosteroids, colchicine, cyclophosphamide and IL1 antagonists.
Medical Therapy
- There is no definitive treatment for cholesterol emboli syndrome; the mainstay of therapy is supportive care.
- Pharmacologic medical therapies that can be effective for cholesterol emboli syndrome include [1]
- Statins
- Statins can stabilize the atherosclerotic plaques. [2]
- Statins reduce inflammation. [3]
- Statins reduce the risk of developing ESRD and dialysis requirement. [4]
- Corticosteroids [5] [6] [7]
- high dose of corticosteroids has been shown effective but not in the long term.
- Colchicine [8] [9]
- Cyclophosphamide
- IL1 antagonists might be effective due to their anti-inflammatory effects.
- Statins
References
- ↑ Ozkok, Abdullah (2019). "
Cholesterol-embolization syndrome: current perspectives
". Vascular Health and Risk Management. Volume 15: 209–220. doi:10.2147/VHRM.S175150. ISSN 1178-2048. - ↑ Akdim, Fatima; van Leuven, Sander; P. Kastelein, John; G. Stroes, Erik (2007). "Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?". Current Pharmaceutical Design. 13 (10): 1003–1012. doi:10.2174/138161207780487548. ISSN 1381-6128.
- ↑ Tousoulis, Dimitris; Psarros, Costas; Demosthenous, Michael; Patel, Rikhil; Antoniades, Charalambos; Stefanadis, Christodoulos (2014). "Innate and Adaptive Inflammation as a Therapeutic Target in Vascular Disease". Journal of the American College of Cardiology. 63 (23): 2491–2502. doi:10.1016/j.jacc.2014.01.054. ISSN 0735-1097.
- ↑ Woolfson, Robin G; Lachmann, Helen (1998). "Improvement in renal cholesterol emboli syndrome after simvastatin". The Lancet. 351 (9112): 1331–1332. doi:10.1016/S0140-6736(05)79058-9. ISSN 0140-6736.
- ↑ "Cholesterol crystal embolization (CCE): Improvement of renal function with high-dose corticosteroid treatment Desai M, Ram R, Prayaga A, Dakshinamurty K V - Saudi J Kidney Dis Transpl".
- ↑ Stabellini N, Cerretani D, Russo G, Rizzioli E, Gilli P (2002). "[Renal atheroembolic disease: evaluation of the efficacy of corticosteroid therapy]". G Ital Nefrol (in Italian). 19 (1): 18–21. PMID 12165941.
- ↑ Yücel, A. E.; Kart-Köseoglu, H.; Demirhan, B.; Özdemir, F. N. (2005). "Cholesterol crystal embolization mimicking vasculitis: success with corticosteroid and cyclophosphamide therapy in two cases". Rheumatology International. 26 (5): 454–460. doi:10.1007/s00296-005-0012-4. ISSN 0172-8172.
- ↑ . doi:10.1016/j.atherosclerosis.2017.12.02. Missing or empty
|title=(help) - ↑ Robertson, Stacy; Martínez, Gonzalo J.; Payet, Cloe A.; Barraclough, Jennifer Y.; Celermajer, David S.; Bursill, Christina; Patel, Sanjay (2016). "Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation". Clinical Science. 130 (14): 1237–1246. doi:10.1042/CS20160090. ISSN 0143-5221.